Lymphoma developing in a patient with long-term antitumor necrosis factor therapy

Giovana Serrão Fensterseifer; André Vicente Esteves de Carvalho; Ana Letícia Boff; Joel Schwartz

doi:10.5826/dpc.1203a132

Lymphoma developing in a patient with long-term antitumor necrosis factor therapy

Authors

Giovana Serrão Fensterseifer Dermatology Department at Hospital, São Lucas da PUCRS, Porto Alegre, Brazil
André Vicente Esteves de Carvalho Dermatologist at Private Practice, Dermatologist at Hospital Moinhos de Vento, Porto Alegre- Brazil
Ana Letícia Boff Pathologist at Private Practice, Pathologist at Dermatology Department at Santa Casa de Misericórdia de Porto Alegre, Porto Alegre- Brazil
Joel Schwartz Dermatologist at Private Practice, Porto Alegre- Brazil

Keywords:

lymphoma, antiTNF, adalimumab, psoriasis

References

Wong AK, Kerkoutian S, Said J, Rashidi H, Pullarkat ST. Risk of lymphoma in patients receiving antitumor necrosis factor therapy: a meta-analysis of published randomized controlled studies. Clin Rheumatol. 2012;31(4):631-636. DOI: 10.1007/s10067-011-1895-y. PMID: 22147207.2. Fiorentino D, Ho V, Lebwohl MG, et at. Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry. J Am Acad Dermatol. 2017;77(5):845-854. DOI: 10.1016/j.jaad.2017.07.013. PMID: 28893407.

Downloads

Published

2022-07-28

Issue

2022 Vol 12, No 3 | July

Section

Research Letter

License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.

How to Cite

Fensterseifer GS, Esteves de Carvalho AV, Boff AL, Schwartz J. Lymphoma developing in a patient with long-term antitumor necrosis factor therapy. Dermatol Pract Concept. 2022;12(3):e2022132. doi:10.5826/dpc.1203a132